We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




German Biotech Company to Market Bromodeoxyuridine Antibody Clone

By LabMedica International staff writers
Posted on 17 Nov 2010
A German biotechnology company has been awarded the exclusive right to commercialize the most popular bromodeoxyuridine (BrdU) antibody clone for research applications.

Bromodeoxyuridine (BrdU) is a synthetic thymidine analog that can be incorporated into a cell's DNA when the cell is dividing (during the S-phase of the cell cycle). More...
Antibodies against BrdU that are conjugated to fluorescent markers can be used to label these cells, thereby providing visual evidence of cell division.

The most popular BrdU antibody clone, BU1/75 was developed at the Institute of Cancer Research (London, United Kingdom) where it was initially called ICR1. Exclusive worldwide rights to market this antibody have now been awarded to AbD Serotec, the research and diagnostic antibodies unit of MorphoSys AG (Munich, Germany). The agreement will allow development of diagnostic procedures to proceed in a range of formats suitable for various applications such as ELISA, flow cytometry, and immunohistochemistry.

"With this agreement AbD Serotec will become the sole supplier of this important BrdU antibody, a powerful tool to detect cell proliferation and cell kinetics assays," said Dieter Feger, head of AbD Serotec. "This product complements our comprehensive range of high quality cell biology reagents covering key research areas such as apoptosis, cancer, cell signaling, and cell morphology."

Related Links:
Institute of Cancer Research
MorphoSys AG




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Immunofluorescence Analyzer
IFA System
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.